Last reviewed · How we verify

NCT05756595

A Clinical Study of Freshly Manufactured 35kDa Hyaluronan Fragment in the Treatment of Pain

Completed NA Last updated 6 March 2023
What this trial tests

NA trial testing HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089) in Shoulder Pain in 36 participants. Completed in 8 February 2023.

Timeline
6 July 2020
Primary endpoint
29 December 2022
8 February 2023

Quick facts

Lead sponsorDove Medical Press Ltd
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment36
Start date6 July 2020
Primary completion29 December 2022
Estimated completion8 February 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Dove Medical Press Ltd — full company profile →

Who can join

Adults 39 to 63, any sex, with Shoulder Pain or Neck Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Local used high molecular weight Hyaluronan (HA) with high viscosity has a variety of receptors in the human body, including CD44, LYVE-1, RHAMM, HARE, Siglec-9, TLR2, CEMIP and TMEM2. Intra-articular local injection of HA has a certain degree of analgesic effect. Local injection of HA into the nerve trunk directed by ultrasound was used for the treatment of neuropathic pain. It was reported that the analgesic effect of HA is regulated by TRPV1 ion channels. This study hypothesizes that hyaluronidase cleaves HA to generate low molecular weight HA fragments HA35 with good tissue permeability, which may bind to a variety of HA receptors on the cell surface within the tissues and produce a broad-spectrum analgesic effect. In this study, 35kDa Hyaluronan fragment HA35 was prepared by mixing hyaluronidase PH20 injection and high molecular weight Hyaluronan (HA) injection at room temperature for 20 minutes. In this study, hyaluronidase injection and Hyaluronan injection were off-label used to conduct an investigator-initiated study (IIT or IIS) for the treatment of herpes zoster and shoulder, neck, back and temporal pain.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Characterization, Bioactivity, and Biodistribution of 35 kDa Hyaluronan Fragment.
    Gantumur MA, Jia X, Hui JH, Barber C, et al · · 2024 · cited 9× · PMID 38255712 · DOI 10.3390/life14010097

Verify or expand the search:

Other trials of HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)

Trials testing the same drug.

Other recruiting trials for Shoulder Pain

Currently open trials in the same condition.

Other Dove Medical Press Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05756595.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing